More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome –Sub-Analysis of JAPAN-ACS Study (Q42950118)

From Wikidata

Jump to navigation Jump to search

scientific article published on July 28, 2010

Language	Label	Description	Also known as
English	More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome –Sub-Analysis of JAPAN-ACS Study	scientific article published on July 28, 2010

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome--sub-analysis of JAPAN-ACS study (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

More Intensive Lipid Lowering is Associated with Regression of Coronary Atherosclerosis in Diabetic Patients with Acute Coronary Syndrome –Sub-Analysis of JAPAN-ACS Study (English)

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

atherosclerosis

1 reference

based on heuristic

inferred from title

10

object named as

Satoshi Saito

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1

object named as

Hidenori Arai

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675955

14 June 2024

author name string

Takafumi Hiro

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Takeshi Kimura

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Takeshi Morimoto

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Katsumi Miyauchi

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Yoshihisa Nakagawa

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Masakazu Yamagishi

7

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Yukio Ozaki

8

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Kazuo Kimura

9

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Tetsu Yamaguchi

11

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Hiroyuki Daida

12

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Masunori Matsuzaki

13

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

JAPAN-ACS Investigators

14

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20675955

14 June 2024

publication date

28 July 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

full work available at URL

https://www.jstage.jst.go.jp/article/jat/17/10/17_5660/_pdf

Portable Document Format

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20675955

14 June 2024

Journal of Atherosclerosis and Thrombosis

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

1096-1107

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial

2

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Intensive versus moderate lipid lowering with statins after acute coronary syndromes

3

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Intensive lipid lowering with atorvastatin in patients with stable coronary disease

4

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial

5

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial

6

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial

7

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH Study

8

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS

9

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome--serial intravascular ultrasound observations from the Japan Assessment of Pitavastatin and Atorvastatin i

10

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

High-density lipoprotein, but not low-density lipoprotein cholesterol levels influence short-term prognosis after acute coronary syndrome: results from the MIRACL trial

11

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events

12

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Usefulness of serum high-density lipoprotein cholesterol level as an independent predictor of one-year mortality after percutaneous coronary interventions

13

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Japan assessment of pitavastatin and atorvastatin in acute coronary syndrome (JAPAN-ACS): rationale and design

14

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Application of intravascular ultrasound in anti-atherosclerotic drug development

15

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (COSMOS).

16

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines

17

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Goals of dyslipidemia management

18

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Extended-release niacin or ezetimibe and carotid intima-media thickness.

19

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Measurement performance of reagent manufacturers by Centers for Disease Control and Prevention/Cholesterol Reference Method Laboratory Network lipid standardization specified for metabolic syndrome-focused health checkups program in Japan

20

1 reference

10.5551/JAT.5660

https://api.crossref.org/works/10.5551/JAT.5660

14 June 2024

Identifiers

10.5551/JAT.5660

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42950118&oldid=2179267982"